Prostate Cancer - Results from #1940

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. November 3, 2023

Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression. November 3, 2023

MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer. November 2, 2023

Effect of a Home-based Walking Intervention on Cardiopulmonary Fitness and Quality of Life Among Men with Prostate Cancer on Active Surveillance: The Active Surveillance Exercise Randomized Controlled Trial. November 2, 2023

Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. November 2, 2023

Prostate Cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National Cancer Database. November 2, 2023

Outcomes of salvage robot-assisted radical prostatectomy in patients who had primary focal versus whole-gland ablation: a multicentric study. November 2, 2023

CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer. November 1, 2023

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. November 1, 2023

Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. November 1, 2023

Racial disparity in the utilization of immunotherapy for advanced prostate cancer. November 1, 2023

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. November 1, 2023

Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial. October 31, 2023

Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer. October 31, 2023

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer. October 31, 2023

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. October 30, 2023

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. October 30, 2023

Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needles. October 30, 2023

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. October 30, 2023

Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy. October 30, 2023

Page 98 of 1439